Bristol-Myers Squibb Co: Is It A Buy? -

Bristol-Myers Squibb Co: Is It A Buy?

Aug 11, 2024Jeremy ParkinsonFinance, No picture0

Image Source: UnsplashAs part of an ongoing series, we typically conduct an analysis on one of the companies in our screens each week. This week, we thought we’d take a look at one of the cheapest stocks in our screens: Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co (BMY)
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.A quick look at the share price history over the past twelve months shows that the price is down approximately 21.99%. Here’s a brief look at why the company is undervalued.Image Source: Google Finance

Key Stats

Market cap: $97.64 billion

Enterprise value: $145.04 billion

Operating Earnings

Operating earnings: $8.17 million

Acquirer’s Multiple

Acquirer’s multiple: 17.70

Free Cash Flow (TTM)

Free cash flow: $12.95 billion

FCF/MC Yield Percentage

FCF/MC yield: 13.26

Shareholder Yield Percentage

Shareholder yield: 9.00

Other Indicators

Piotroski F score: 4

Dividend yield percentage: 4.90

ROA (five-year average percentage): 9

More By This Author:American Express Co. DCF Valuation: Is The Stock Undervalued?McDonald’s Corp Valuation: Is The Stock Undervalued?Why Unilever PLC Stock Is A Buy